Baidu
map

Blood:从微流体看血小板和活化内皮的相互作用。

2017-10-12 qinqiyun MedSci原创

本综述主要是基于体外流式实验和体内血栓形成实验的交叉参考对血小板-内皮界面进行阐述。

一直以来,均认为体外流式实验和体内血栓形成研究对阐述血管壁受损后血小板血栓形成机制至关重要。近年来,逐渐发现血小板还在炎症过程中发挥调节作用,如动脉粥样硬化。其中一个关键元素是血小板、凝血系统、白细胞和活化内皮之间的复杂的交联。

本综述基于体外流式实验和体内血栓形成实验的交叉参考对血小板-内皮界面进行阐述。

血小板和活化的内皮细胞之间的相互作用机制:

1)血小板通过血小板糖蛋白Ib-IX-V与内皮细胞释放的血管性血友病因子相互作用而发生滚动,P选择素与P选择素糖蛋白配体相结合;

2)血小板通过血小板αIIbβ3与内皮细胞αvβ3和细胞间黏附分子l结合而黏附到血管内皮;

3)凝血酶、血小板反应蛋白-1-CD36轴和环氧化酶1在随后的血小板活化和稳定血栓形成过程中发挥了激活作用。

此外,本文还讨论了血小板对白细胞迁移(动脉粥样硬化形成过程的关键过程)的刺激作用的分子机制。

原始出处:

Danielle M. Coenen, Tom G. Mastenbroek, and Judith M.E.M. Cosemans.Platelet interaction with activated endothelium: mechanistic insights from microfluidics.Blood.October 10,2017. https://doi.org/10.1182/blood-2017-04-780825

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909220, encodeId=ddae190922043, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Nov 26 09:30:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471557, encodeId=7ec214e1557dd, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Oct 14 08:30:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252268, encodeId=b59a252268ce, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Oct 12 19:08:07 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252255, encodeId=18e0252255cd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 12 18:09:03 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909220, encodeId=ddae190922043, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Nov 26 09:30:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471557, encodeId=7ec214e1557dd, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Oct 14 08:30:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252268, encodeId=b59a252268ce, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Oct 12 19:08:07 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252255, encodeId=18e0252255cd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 12 18:09:03 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-10-14 ylz8405
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909220, encodeId=ddae190922043, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Nov 26 09:30:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471557, encodeId=7ec214e1557dd, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Oct 14 08:30:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252268, encodeId=b59a252268ce, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Oct 12 19:08:07 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252255, encodeId=18e0252255cd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 12 18:09:03 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-10-12 139****0239

    henhao

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1909220, encodeId=ddae190922043, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Nov 26 09:30:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471557, encodeId=7ec214e1557dd, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Oct 14 08:30:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252268, encodeId=b59a252268ce, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Oct 12 19:08:07 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252255, encodeId=18e0252255cd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 12 18:09:03 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-10-12 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Blood:在血小板生产和血栓形成过程中,III型磷脂酰肌醇激酶——Vps34的双重作用。

Vps34是唯一的III型磷脂酰肌醇激酶,为揭示其在巨噬细胞(MKs)和血小板中的作用,研究人员在巨噬细胞/血小板谱系中建立了一个敲除Vps34基因的小鼠模型(Pf4-Cre/Vps34lox/lox)。敲除巨噬细胞的Vps34基因导致其调节蛋白Vps15缺失,并与血小板减少和血小板颗粒异常相关。

J Periodontol:富含血小板纤维蛋白在骨下袋再生中的应用:一项随机对照试验

富含血小板纤维蛋白(PRF)是一种自体的非输血获得的血成分,富含高浓度的血小板。它是在稠密的纤维蛋白基质中混合了白细胞、血小板和生长因子,并且可以被用做治疗生物材料。这篇研究是为了评估再生治疗骨下袋辅助应用PRF的效果,并与开放皮瓣清创术相比较。

ESC2017:对于急性冠脉综合征患者双重抗血小板治疗需谨慎!

ESC会议今天提出的新研究表明,对于需要经皮冠状动脉介入治疗(PCI)的急性冠状动脉综合征(ACS)患者,根据现行的双重抗血小板治疗指南(DAPT)治疗可能不如遵守较老的指南。

JACC:高血小板反应性与出血风险关系密切!

根据JACC在线发表的一项研究:药物洗脱支架植入术后,氯吡格雷与高血小板反应性及两年缺血和出血发生率之间存在着密切的关系。

CLIN CANCER RES:血小板源Tgfβ1在卵巢癌进展中扮演的角色

转化生长因子β1(Tgfβ1)在肿瘤中扮演着重要角色。绝大部分Tgfβ1来自血小板。CLIN CANCER RES近期发表了一篇文章,研究血小板Tgfβ1在卵巢癌进展中发挥的作用以及这种作用是否仅限与远处转移还是与原发肿瘤生长也有关系。

Blood:敲除CK2β基因可以减少血栓形成,甚至可降低中风风险。

血小板,巨核细胞分裂出的无核细胞质,在止血和动脉血栓形成过程中发挥重要作用。酪蛋白激酶2(CK2)在巨核细胞和血小板中都可以检测到,对于CK2依赖性信号通路对巨噬细胞/血小板的病理生理机制的作用尚不明确。

Baidu
map
Baidu
map
Baidu
map